These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21894546)

  • 1. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.
    Zinzani PL; Rigacci L; Stefoni V; Broccoli A; Puccini B; Castagnoli A; Vaggelli L; Zanoni L; Argnani L; Baccarani M; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):4-12. PubMed ID: 21894546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
    Johnson P; Federico M; Kirkwood A; Fosså A; Berkahn L; Carella A; d'Amore F; Enblad G; Franceschetto A; Fulham M; Luminari S; O'Doherty M; Patrick P; Roberts T; Sidra G; Stevens L; Smith P; Trotman J; Viney Z; Radford J; Barrington S
    N Engl J Med; 2016 Jun; 374(25):2419-29. PubMed ID: 27332902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.
    Orlacchio A; Schillaci O; Gaspari E; Della Gatta F; Danieli R; Bolacchi F; Ragano Caracciolo C; Mancini A; Simonetti G
    Radiol Med; 2012 Oct; 117(7):1250-63. PubMed ID: 22327919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
    Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
    Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.
    Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A
    Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
    Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
    J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
    Hartridge-Lambert SK; Schöder H; Lim RC; Maragulia JC; Portlock CS
    Cancer; 2013 Mar; 119(6):1203-9. PubMed ID: 23132361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
    Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
    Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
    Radford J; Illidge T; Counsell N; Hancock B; Pettengell R; Johnson P; Wimperis J; Culligan D; Popova B; Smith P; McMillan A; Brownell A; Kruger A; Lister A; Hoskin P; O'Doherty M; Barrington S
    N Engl J Med; 2015 Apr; 372(17):1598-607. PubMed ID: 25901426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
    Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
    Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
    Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
    Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
    Biggi A; Gallamini A; Chauvie S; Hutchings M; Kostakoglu L; Gregianin M; Meignan M; Malkowski B; Hofman MS; Barrington SF
    J Nucl Med; 2013 May; 54(5):683-90. PubMed ID: 23516309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
    Gallamini A; Hutchings M; Rigacci L; Specht L; Merli F; Hansen M; Patti C; Loft A; Di Raimondo F; D'Amore F; Biggi A; Vitolo U; Stelitano C; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A
    J Clin Oncol; 2007 Aug; 25(24):3746-52. PubMed ID: 17646666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.